Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Andy Hargreaves saying upside from the launch of iPhone 8 is already reflected in the shares. An "extremely strong iPhone 8 cycle" is being priced into the stock while little weight is being given to gross margins, supply issues, or the likelihood for declines beyond the iPhone 8, Hargreaves tells investors in a research note. 2. Perrigo (PRGO) downgraded to Underperform from Sector Perform at RBC Capital with analyst Randall Stanicky saying the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. 3. Endocyte (ECYT) downgraded to Neutral from Outperform at Wedbush and to Market Perform from Outperform at Cowen. 4. Affiliated Managers (AMG) was downgraded to Neutral from Buy at Citi while Federated Investors (FII) was downgraded to Sell from Neutral. 5. Veeva (VEEV) downgraded to Equal Weight from Overweight at Morgan Stanley with the firm's analyst saying the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

As noted earlier, Wedbush downgraded Endocyte to Neutral from Outperform. Analyst David Nierengarten downgraded the stock after the company reported that the level of activity observed in trials did not support further development of its EC1456 or its EC1169 in taxane-naive CRPC. The company will only develop EC1169 in the taxanes-exposed CRPC population going forward and will discontinue EC1456, the analyst reported. He removed all sales from both drugs from his model ,citing uncertain initial results of 1169 in the taxane-exposed population. Target to $2 from $8.

As reported previously, Cowen analyst Boris Peaker downgraded Endocyte to Market Perform from Outperform due to the failure of its lead asset, EC1456, and higher uncertainty with its pipeline.